EUVIMEDEUVIMED entdecken
Open Access

Syk-dependent homologous recombination activation promotes cancer resistance to DNA targeted therapy

Qin Zhou, Xinyi Tu, Xiaonan Hou, Jia Yu, Fei Zhao, Jinzhou Huang, Jake Kloeber, Anna Olson, Ming Gao, Kuntian Luo, Shouhai Zhu, Zheming Wu und 10 weitere

Drug Resistance Updates · 2024-05 · 74 · 101085

DOI: 10.1016/j.drup.2024.101085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2024-05. Verfasst von Qin Zhou und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, United States. Hauptthemen laut MEDLINE: Syk Kinase, Homologous Recombination, DNA Breaks, Double-Stranded, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NIGMS NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Enhanced DNA repair is an important mechanism of inherent and acquired resistance to DNA targeted therapies, including poly ADP ribose polymerase (PARP) inhibition. Spleen associated tyrosine kinase (Syk) is a non-receptor tyrosine kinase acknowledged for its regulatory roles in immune cell function, cell adhesion, and vascular development. This study presents evidence indicating that Syk expression in high-grade serous ovarian cancer and triple-negative breast cancers promotes DNA double-strand break resection, homologous recombination (HR), and subsequent therapeutic resistance. Our investigations reveal that Syk is activated by ATM following DNA damage and is recruited to DNA double-strand breaks by NBS1. Once localized to the break site, Syk phosphorylates CtIP, a pivotal mediator of resection and HR, at Thr-847 to promote repair activity, particularly in Syk-expressing cancer cells. Inhibition of Syk or its genetic deletion impedes CtIP Thr-847 phosphorylation and overcomes the resistant phenotype. Collectively, our findings suggest a model wherein Syk fosters therapeutic resistance by promoting DNA resection and HR through a hitherto uncharacterized ATM-Syk-CtIP pathway. Moreover, Syk emerges as a promising tumor-specific target to sensitize Syk-expressing tumors to PARP inhibitors, radiation and other DNA-targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Syk KinaseHomologous RecombinationDNA Breaks, Double-StrandedDrug Resistance, NeoplasmHumansFemalePhosphorylationPoly(ADP-ribose) Polymerase InhibitorsOvarian NeoplasmsDNA RepairAtaxia Telangiectasia Mutated ProteinsTriple Negative Breast NeoplasmsAnimalsCell Line, TumorDNA Damage

Stichwörter der Autor:innen

Cancer resistanceCtIPDNA targeted therapyHomologous recombinationSyk

Substanzen

Syk KinaseSYK protein, humanPoly(ADP-ribose) Polymerase InhibitorsAtaxia Telangiectasia Mutated Proteins

Autor:innen und Institutionen

  • Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, United States.
  • Department of Oncology, Mayo Clinic, Rochester, MN 55905, United States.
  • Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, United States.
  • AMITA Health Saint Joseph Hospital Chicago, Chicago, IL 60657, United States.
  • Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, United States.
  • Nursing Department, Rochester Community and Technical College, Rochester, MN 55904, United States.

Förderung

  • NICHD NIH HHS
  • NIGMS NIH HHS
  • NCI NIH HHS
  • NICHD
  • Mayo Clinic
  • American Society for Radiation Oncology
  • National Institutes of Health
  • Mayo Foundation for Medical Education and Research

Zitieren

APA

Zhou, Q., Tu, X., Hou, X., Yu, J., Zhao, F., Huang, J., Kloeber, J., Olson, A., Gao, M., Luo, K., Zhu, S., Wu, Z., Zhang, Y., Sun, C., Zeng, X., Schoolmeester, K. J., Weroha, J. S., Hu, X., Jiang, Y., …, & Lou, Z. (2024). Syk-dependent homologous recombination activation promotes cancer resistance to DNA targeted therapy. Drug Resistance Updates, 74, 101085. https://doi.org/10.1016/j.drup.2024.101085

Vancouver

Zhou Q, Tu X, Hou X, Yu J, Zhao F, Huang J, et al. Syk-dependent homologous recombination activation promotes cancer resistance to DNA targeted therapy. Drug Resistance Updates. 2024;74:101085. doi:10.1016/j.drup.2024.101085

BibTeX
@article{Zhou2024,
  author = {Zhou, Qin and Tu, Xinyi and Hou, Xiaonan and Yu, Jia and Zhao, Fei and Huang, Jinzhou and Kloeber, Jake and Olson, Anna and Gao, Ming and Luo, Kuntian and Zhu, Shouhai and Wu, Zheming and Zhang, Yong and Sun, Chenyu and Zeng, Xiangyu and Schoolmeester, Kenneth J and Weroha, John S and Hu, Xiwen and Jiang, Yanxia and Wang, Liewei and Mutter, Robert W and Lou, Zhenkun},
  title = {Syk-dependent homologous recombination activation promotes cancer resistance to DNA targeted therapy},
  journal = {Drug Resistance Updates},
  year = {2024},
  volume = {74},
  pages = {101085},
  doi = {10.1016/j.drup.2024.101085}
}
Kostenlos starten →